These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 31732822)

  • 1. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumonia in children with juvenile idiopathic arthritis in Finland 1999-2014: a nationwide retrospective register linkage study.
    Salonen PH; Säilä H; Salonen JH; Linna M; Helminen M; Kauppi MJ
    Clin Exp Rheumatol; 2018; 36(3):502-507. PubMed ID: 29303705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.
    Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V
    Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian reserve in children with juvenile idiopathic arthritis using biologic disease-modifying anti-rheumatic drugs.
    Ozer Y; Yildiz M; Turan H; Tarcin G; Bingol Aydin D; Gunalp A; Haslak F; Kilic Konte E; Aslan E; Koker O; Bayramoglu E; Sahin S; Adrovic A; Barut K; Kasapcopur O; Evliyaoglu O
    Clin Rheumatol; 2024 Jan; 43(1):399-406. PubMed ID: 37646858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of methotrexate in children with rheumatic diseases.
    Gutiérrez-Suárez R; Burgos-Vargas R
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S122-7. PubMed ID: 21044445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
    Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
    Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
    Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
    Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of systemic JIA: When do we need a biologic? Real world data of a single center.
    Adiguzel Dundar H; Acari C; Turkucar S; Unsal E
    Mod Rheumatol; 2021 May; 31(3):684-690. PubMed ID: 32343644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
    Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y
    Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
    Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
    Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
    Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
    Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
    Grazziotin LR; Currie G; Twilt M; Ijzerman MJ; Kip MMA; Koffijberg H; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung RSM; Marshall DA
    Pediatr Rheumatol Online J; 2022 Apr; 20(1):25. PubMed ID: 35410419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden.
    Berthold E; Månsson B; Kahn R
    Arthritis Res Ther; 2019 Oct; 21(1):218. PubMed ID: 31661011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bloodstream infections among children with juvenile idiopathic arthritis: a prospective study from the onset of disease.
    Salonen PH; Säilä H; Salonen JH; Vuorela M; Kautiainen H; Lyytikäinen O; Kauppi MJ; Leirisalo-Repo M; Repo H
    Clin Exp Rheumatol; 2014; 32(6):979-83. PubMed ID: 25436839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.